Opna Bio
Oncology Therapeutics · Biologics & Biosimilars
Overview
Opna Bio is a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics. The company’s lead program is OPN-6602, a dual EP300/CBP inhibitor, currently in a Phase 1 clinical trial in patients with multiple myeloma.
Funding and backers
Team
51-200
employees, estimated range
Backers
2
Longitude Capital, Menlo Ventures
Momentum
0/100
no fresh signals
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Dec 1, 2022
Launched Opna Bio launches to continue Plexxikon's work · Chemical & Engineering News
2020
Founded
Registers and programsofficial lists and records that name the company
| Legal entity | Opna Bio SA | its site |
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
EnteroBiotix is a clinical-stage biopharmaceutical company developing best-in-class full-spectrum microbial therapeutics.
Veradermics is a dermatologist-founded, late clinical-stage biopharmaceutical company.
CAMPfield Therapeutics is a clinical-stage biopharmaceutical company developing prifemilast, a once-daily oral PDE4B-selective inhibitor…
AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming HBV treatment for cure and advancing…
ImmunoMet Therapeutics is a clinical-stage oncology company developing lixumistat (IM156), a best-in-class OxPhos inhibitor targeting the…
Stelexis BioSciences is a clinical-stage biopharmaceutical company created to accelerate novel treatments that aim to eradicate…
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Longitude CapitalVia a fund
78 portfolio companies: Zenas BioPharma, Mobia Medical, Inc. and 76 more
Menlo VenturesVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Opna Bio SA
The Nature Index tracks the affiliations of scientific articles from high-quality publications. The research profile for Opna Bio SA reflects the research output of authors from Opna Bio SA who published articles in the 145 journals included in the Nature
Read more
Report
Opna Bio Announces Fast Track Designation Granted to OPN-6602 for the Treatment of Multiple Myeloma
SOUTH SAN FRANCISCO, Calif., April 15, 2026--Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Tr
Read more
Report
Opna Bio's zavabresib gains FDA orphan status
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--January 21, 2026--Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and de
Read more
Report
Opna Bio Announces Orphan Drug Designation Granted to OPN-2853 (Zavabresib) for the Treatment of Myelofibrosis
SOUTH SAN FRANCISCO, Calif., January 21, 2026--Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, today announced that OPN-2853, a bromodomain and extra-terminal motif (BET) small
Read more
Report
Opna Bio Announces Interim Data from Phase 1 Combination Study of OPN-2853 with Ruxolitinib in Patients with Advanced Myelofibrosis
Preclinical Data with OPN-6602 in Multiple Myeloma Show 100% Tumor Regression in Combination Treatment Studies Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development
Read more
Report
Opna Bio Presents Promising Preclinical Data in Multiple Myeloma with OPN-6602 and in Malignant Mesothelioma with OPN-9840 Showing Significant Tumor Growth Inhibition at the ...
Read more
Report
Opna Bio launches to continue Plexxikon's work
Chemical & Engineering News (C&EN): Keeping you up to date with the chemistry news that matters most. Published by the American Chemical Society.
Read more
Report